Skip to Main Content
Yale School of Medicine
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Yale School of Medicine
/
Rheumatology, Allergy & Immunology
MENU
Yale School of Medicine
MENU
Rheumatology, Allergy & Immunology
Rheumatology
Patient Care
Research
Clinical & Translational Research Lab (YR-CTRL)
Immune Profiling
Inflammation and Innate Immunity
In Vivo Imaging Facility
Lupus
Lyme Disease
Microbiome Research
Research Training Faculty
Clinical Trials
Publications
Yale Rheumatology Fellowship Training
Clinical Training
Research Training
Current Fellows and Graduate Information
Faculty
Philanthropy
Allergy & Immunology
Patient Care
Research
Publications
Education & Training
Clinical Training
Research Training
Seminars
Application
Current Fellows
Faculty
Contact Us
Faculty
News & Events
Newsletter
Winter 2023
May 2023
September 2023
December 2023
February 2024
June 2024
September 2024
YSM Home
INFORMATION FOR
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Home
Rheumatology
Research
Clinical & Translational Research Lab (YR-CTRL)
Immune Profiling
Inflammation and Innate Immunity
In Vivo Imaging Facility
Lupus
Lyme Disease
Microbiome Research
Research Training Faculty
Clinical Trials
Publications
Clinical Trials
A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumor
Lung
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Thyroid
A Phase III Study of Targeted Therapy vs. Chemotherapy in Patients with Thyroid Cancer
Lung
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Other Hematopoietic
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Show More
Your browser is antiquated and no longer supported on this website. Please update your browser or switch to Chrome, Firefox or Safari.
You can update your IE here:
https://support.microsoft.com/en-us/help/17621/internet-explorer-downloads
[8330,3053]
{"namedChunks":["modules-page-components-ComponentWrapper","features-clinical-trial-components-ClinicalTrialListing","modules-footer-components-Footer"]}